Roivant Sciences Ltd.
ROIV
$11.92
$0.110.93%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -105.17% | -98.75% | -97.64% | 882.87% | 638.83% |
| Total Depreciation and Amortization | -38.98% | -45.12% | 112.80% | 67.08% | 14.30% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 94.95% | 89.62% | 90.06% | -2,962.51% | -2,181.92% |
| Change in Net Operating Assets | -27.06% | -1,225.11% | -403.35% | -33.88% | -431.01% |
| Cash from Operations | 17.51% | 25.17% | 39.16% | 39.66% | 15.82% |
| Capital Expenditure | -299.82% | -225.47% | -314.38% | -83.21% | 58.40% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -95.62% | -95.62% | -97.06% | 169,384.76% | 78,128.51% |
| Other Investing Activities | 2,620.73% | 15,053.60% | 60,834.06% | 1,255.87% | 105.79% |
| Cash from Investing | -91.49% | -70.65% | -91.34% | 7,008.94% | 14,273.96% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -186.14% | -120.10% | -278.70% | -12.64% | 23.99% |
| Issuance of Common Stock | 380.47% | 29.18% | 13.82% | -87.27% | -87.27% |
| Repurchase of Common Stock | -11.50% | -3,127.87% | -10,298.05% | -10,007.72% | -10,007.72% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -52.76% | -52.76% | -100.00% | 252.49% | 252.49% |
| Cash from Financing | -156.45% | -364.86% | -245.88% | -178.70% | -168.15% |
| Foreign Exchange rate Adjustments | -34.00% | -307.54% | -259.38% | -372.65% | -372.65% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -118.39% | -103.30% | -119.81% | 2,353.86% | 937.31% |